The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1508
Lesinurad (Zurampic) for Gout-Associated Hyperuricemia
The full article is available to subscribers Subscriber Login   

The FDA has approved lesinurad (Zurampic – Ironwood), a uric acid transporter 1 (URAT1) inhibitor, for adjunctive treatment of gout-associated hyperuricemia in patients whose serum uric acid levels fail to reach goal with xanthine oxidase inhibitor monotherapy.

STANDARD TREATMENT — Recent guidelines offer conflicting views on the benefits of monitoring serum uric acid levels and the appropriate use of urate-lowering therapy in patients with gout,1-3 but most expert clinicians still initially treat gout-associated hyperuricemia with a xanthine oxidase inhibitor such as allopurinol or febuxostat with the goal of reducing the serum uric acid level below 6.0 mg/dL (and preferably below 5.0 mg/dL). The uricosuric drug probenecid can be used for add-on therapy if target serum uric acid levels are not reached with a xanthine oxidase inhibitor alone or for initial therapy ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Lesinurad (Zurampic) for Gout-Associated Hyperuricemia
Article code: 1508b
 Electronic, downloadable article - $25